Recent 8-K filings for GOVX

• May 19, 2026, 5:04 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01

  GeoVax prices $3M private placement offering at $1.4799 per unit with warrants

  Gross proceeds ~$3M; net proceeds ~$2.7M after placement agent fees and expenses.

• May 14, 2026, 4:23 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3

  Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).

• May 7, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  GeoVax raises ~$595k via warrant inducement; issues new warrants for 1M shares at $1.65

  Holders exercise warrants for 501,144 shares; gross proceeds ~$595k before fees.

• April 15, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026

  Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.

• March 31, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01

  GeoVax raises ~$863k via warrant exercise inducement, issues new warrants for 1.27M shares

  Existing warrant holders exercise 634,658 shares at reduced $1.36/share, gross proceeds ~$863k.

• February 17, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  GeoVax raises ~$1M gross in registered direct offering priced at $2.31/share

  Offering of 432,902 shares (or pre-funded warrants) at $2.31/share; net proceeds ~$865,000.

• January 12, 2026, 6:59 PM ET other material materiality 0.60 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  GeoVax Labs effects 1-for-25 reverse stock split effective January 9, 2026

  Each 25 shares of common stock automatically combined into 1 share; no fractional shares issued.

• December 22, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 7.01item 9.01

  GeoVax raises ~$3.2M in public offering of 13.2M units at $0.245/unit

  Offering of 13,244,896 common units at $0.245/unit, each consisting of one share plus warrants for two shares.

• November 26, 2025, 6:59 PM ET other material materiality 0.40 neutral item 5.07item 9.01

  GeoVax stockholders approve reverse stock split and warrant share issuance at special meeting

  Reverse split authorized at ratio between 1:10 and 1:25, with 11.85M votes for and 2.16M against.

• November 13, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated

  Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.

• September 30, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 3.02item 7.01item 9.01

  GeoVax raises ~$2.5M in registered direct offering; issues shares and warrants at $0.63

  3,968,256 shares sold at $0.63 each with warrants to buy 11,904,768 shares at $0.63.

• August 1, 2025, 7:59 PM ET regulatory materiality 0.70 negative item 3.01item 9.01 ◈ Listing & Compliance Notices

  GeoVax receives Nasdaq deficiency notice for bid price below $1.00

  Nasdaq notified GeoVax on July 31, 2025, that closing bid price was below $1.00 for 30 consecutive business days.

• July 29, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance

  Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.

• July 2, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 7.01item 9.01

  GeoVax raises ~$6M in public offering of 9.2M units at $0.65/unit

  Offering of 9,235,000 units at $0.65/unit, each unit = 1 share + warrant to buy 2 shares.

• June 5, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  GeoVax shareholders elect all seven directors, approve 2025 stock plan and warrant issuance at annual meeting

  All seven director nominees elected; votes for ranged from 1,654,889 to 1,834,828, with 4,368,295 broker non-votes.

• May 1, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025

  Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).

• April 14, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.02

  BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience

  On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.

• March 28, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  GeoVax FY2024 net loss $25.0M; BARDA award yields $4.0M revenue; key trials advancing

  Net loss $25.0M vs $26.0M in 2023; revenue of $4.0M from BARDA Project NextGen contract (no revenue in 2023).

• March 25, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 7.01item 9.01

  GeoVax Labs raises $4.5M in registered direct offering, amends existing warrants

  Issued 3,435,115 shares or equivalents and common warrants at $1.31/unit, gross proceeds ~$4.5M.

• January 22, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07

  GeoVax shareholders approve issuance of up to 3.78M shares upon warrant exercises in two private placements

  May 2024 warrant exercise proposal approved: 1,294,141 for, 287,649 against, 93,544 abstain.

• December 18, 2024, 6:59 PM ET other material materiality 0.45 neutral item 8.01

  GeoVax Labs adjourns special meeting due to lack of quorum; reconvenes Jan 22, 2025

  Only 32.2% of shares voted; quorum not achieved at Dec 18, 2024 reconvened meeting.

• November 18, 2024, 6:59 PM ET regulatory materiality 0.65 positive item 3.01

  GeoVax Labs regains Nasdaq compliance with $8.5M stockholders' equity

  Received Nasdaq notice on Nov 18, 2024 confirming compliance with Listing Rule 5550(b)(1) based on $8,503,876 stockholders' equity as of Sep 30, 2024.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 8.01item 9.01

  GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned

  Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).

• October 16, 2024, 7:59 PM ET other material materiality 0.35 neutral item 8.01

  GeoVax special meeting adjourned for lack of quorum; reconvenes Nov 12, 2024

  Special meeting reconvened Oct 16, 2024, adjourned without business; only 28.6% of shares represented.

• October 15, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  GeoVax Labs boosts ATM equity offering capacity from $4.5M to $30M

  Maximum aggregate offering price under Sales Agreement with A.G.P./Alliance Global Partners increased from $4,486,846 to $30,000,000.

• October 1, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  GeoVax Labs Special Meeting adjourned for lack of quorum; reconvenes Oct 16

  Special Meeting reconvened Oct 1, 2024, adjourned without business due to insufficient quorum.

• September 25, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 9.01

  GeoVax enters ATM agreement with A.G.P. to sell up to $4.5M in common stock

  ATM offering of up to $4,486,846 in common stock via A.G.P. as agent; commission 3% of gross proceeds.

• September 17, 2024, 7:59 PM ET other material materiality 0.35 neutral item 8.01item 9.01

  GeoVax Labs adjourns special meeting for lack of quorum; reconvenes Oct 1, 2024

  Special meeting on Sept 17, 2024 adjourned with no business conducted due to lack of quorum.

• August 30, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01

  GeoVax raises ~$5.0M in registered direct offering at $5.125/share with warrants

  Offering of 837,500 common shares at $5.125/share and 138,110 pre-funded warrants at $5.12499, exercise price $0.0001.

• August 21, 2024, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 7.01item 9.01

  GeoVax raises ~$8.5M in registered direct offering of 1.7M shares at $5.00 each

  Gross proceeds $8.5M; net proceeds ~$7.855M after fees and expenses.

• August 7, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial

  Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.

• July 12, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01

  GeoVax raises ~$3.1M gross in offering of stock, pre-funded and common warrants

  Offering of 1,085,000 shares (or equivalents) at $2.86; pre-funded warrants for 626,368 shares and common warrants for 2,170,000 shares.

• June 21, 2024, 7:59 PM ET regulatory materiality 0.50 neutral item 3.01item 3.03item 9.01

  GeoVax receives Nasdaq non-compliance notice but regains compliance via warrant amendment

  Company issued 802,844 shares and warrants in $1.3M private placement at $1.68/unit, triggering Nasdaq Rule 5635(d).

• June 18, 2024, 7:59 PM ET other material materiality 0.85 positive item 1.01item 9.01

  GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial

  Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.

• May 24, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

  GeoVax Labs receives Nasdaq delisting notice for failing $2.5M equity minimum

  Notice received May 23, 2024; stockholders' equity as of March 31, 2024 below $2.5M requirement.

• May 23, 2024, 7:59 PM ET other materiality 0.25 neutral item 5.03item 5.07item 9.01

  GeoVax shareholders approve all proposals at annual meeting; quorum reduced to 33 1/3%

  All seven director nominees elected with between 440,096 and 517,969 votes for.

• May 21, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 7.01item 9.01

  GeoVax raises ~$1.3M in registered direct offering and warrant placement

  Sold 220,000 shares and 582,844 pre-funded warrants at $1.68/share; gross proceeds ~$1.3M.

• May 15, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  GeoVax Q1 net loss widens to $5.6M; cash drops to $0.8M, raising going-concern risk

  Net loss of $5.6M ($2.47 per share) vs $4.0M ($2.30 per share) in Q1 2023.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

3 positive 6 negative 29 neutral

source · GOVX on sec.gov